Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebelizumab + bevacizumab + chemotherapy for EGFR-mutated recurrent or metastatic NSCLC
ChiCTR2400087951Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebelizumab, bevacizumab and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective response rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
adebelizumabbevacizumabpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400087951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087951.